Nitric oxide regulates prolidase activity by serine/threonine phosphorylation

Journal of Cellular Biochemistry

Volumn 96, Issue 5, 2005, Pages 1086-1094

  Surazynski, Arkadiusz ^a   Liu, Yongmin ^a   Miltyk, Wojciech ^a   Phang, James M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

cGMP; Nitric oxide; Prolidase; Serine threonine phosphorylation

Indexed keywords

3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; 8 BROMO CYCLIC GMP; COLLAGEN; CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DERIVATIVE; EXOPEPTIDASE; HYDROXYPROLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; LINSIDOMINE; MANGANESE; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE DONOR; PROLINE; PROLINE DIPEPTIDASE; S METHYLPSEUDOTHIOUREA; SERINE; THIOUREA DERIVATIVE; THREONINE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER INVASION; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; COLLAGEN METABOLISM; COLLAGEN SYNTHESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; EXTRACELLULAR MATRIX; GENETIC TRANSFECTION; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CYCLIC GMP; DIPEPTIDASES; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, ENZYMOLOGIC; IMMUNOPRECIPITATION; INFLAMMATION; MATRIX METALLOPROTEINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; NIH 3T3 CELLS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; PEPTIDES; PHOSPHORYLATION; PLASMIDS; SERINE; SIGNAL TRANSDUCTION; THIOUREA; THREONINE; TIME FACTORS; TRANSFECTION; WOUND HEALING;

ANIMALIA;

EID: 28144453502     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.20631     Document Type: Article

References (35)

1. Aktan F. 2004. iNOS-mediated nitric oxide production and its regulation. Life Sci 75:639-653.
2. Bishop A, Anderson JE. 2005. NO signaling in the CNS: From the physiological to the pathological. Toxicology 208:193-205.
3. Boright AP, Scriver CR, Lancaster GA, Choy F. 1989. Prolidase deficiency. Biochemical classification of alleles. Am J Hum Genet 44:731-740.
4. Busek P, Malik R, Sedo A. 2003. Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Intl J Biochem & Cell Biol 36:408-421.
5. Donald SP, Sun XY, Hu CA, Yu J, Mei JM, Valle D, Phang JM. 2001. Proline oxidase, encoded by p53-induced gene-6, catalyzes the generation of proline-dependent reactive oxygen species. Cancer Res 61:1810-1815.
6. Flentke GR, Munoz E, Huber BT, Plaut AG, Kettner CA, Bachovchin WW. 1991. Inhibition of dipeptidylaminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc Natl Acad Sci USA 88:1556-1559.
7. Giustizieri ML, Albanesi C, Scarponi C. 2002. Nitric oxide donors suppress chemokine production by keratinocytes in vitro and in vivo. Am J Pathol 161:1409-1418.
8. Hechtman P. 2001. Prolidase deficiency. In: Scriver CR, Beaudet AL, Sly D, Valle W, editors. The metabolic and molecular basis of inherited disease. New York: McGraw Hill. pp 1839-1956.
9. Ischiropoulos H, Gow A. 2005. Pathophysiological functions of nitric oxide-mediated protein modifications. Toxicology 208:299-303.
10. Jackson SH, Dennis AW, Greenberg M. 1975. Imidodipeptiduria: A genetic defect in recycling of collagen: A method for determining prolidase in erythrocytes. Can Med Assoc J 113:759-763.
11. Koshland DE. 1993. Molecule of the year. Science 262:1953.
12. Liu Y, Borchert GL, Phang JM. 2004. Polyoma enhancer activator 3, an Ets transcription factor mediates the induction of cyclooxygenase-2 by nitric oxide in colorectal cancer cells. J Biol Chem 279:18694-18700.
13. Liu Y, Borchert GL, Donald SP, Surazynski A, Hu CA, Weydert CJ, Oberley LW, Phang JM. 2005. MnSOD inhibits proline oxidase-induced apoptosis in colorectal cancer cells. Carcinogenesis 26:1335-1342.
14. Marcinkiewicz J. 1997. Regulation of cytokine production by eicosanoids and nitric oxide. Arch Immunol Ther Exp 45:163-167.
15. Marcinkiewicz J, Chain BM. 1993. Differential regulation of cytokine production by nitric oxide. Immunology 80:146-150.
16. Marcinkiewicz J, Grabowska A, Chain BM. 1996. Is there a role for nitric oxide in regulation of T cell secretion of IL-2? J Immunol 156:4617-4621.
17. Maxwell SA, Rivera A. 2003. Proline oxidase induces apoptosis in tumor cells, and its expression is frequently absent or reduced in renal carcinoma. J Biol Chem 278:9784-9789.
18. McDonald LJ, Murad F. 1996. Nitric oxide and cyclic GMP signaling. Proc Soc Exp Biol Med 211:1-6.
19. Mei JM, Borchert GL, Donald SP, Phang JM. 2002. Matrix metalloproteinase(s) mediate(s) NO-induced dissociation of beta-catenin from membrane bound E-cadherin and formation of nuclear beta-catenin/LEF-1 complex. Carcinogenesis 23:2119-2122.
20. Miltyk W, Karna E, Wolczynski S, Palka J. 1998. Insulin-like growth factor I-dependent regulation of prolidase activity in cultured human skin fibroblasts. Mol Cell Biochem 189:177-183.
21. Miltyk W, Surazynski A, Kasprzak KS, Fivash MJ, Jr., Buzard GS, Phang JM. 2005. Inhibition of prolidase activity by nickel causes decreased growth of proline auxotrophic CHO cells. J Cell Biochem 94:1210-1217.
22. Mock WL, Green PC, Boyer KD. 1990. Specificity and pH dependence foracylproline cleavage by prolidase. J Biol Chem 265:1960-1965.
23. Myara I, Charpentier C, Lemonnier A. 1982. Optimal conditions for prolidase assay by proline colorimetric determination: Application to iminodipeptiduria. Clin Chim Acta 125:193-205.
24. Myara I, Charpentier C, Lemmonier A. 1984. Minireview: Prolidase and prolidase deficiency. Life Sci 334:1985-1998.
25. Palka JA, Phang JM. 1997. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 1; 67:166-175.
26. Royce PM, Steinmann B. 1993. Prolidase deficiency. In: Royce PM, Steinmann B, editors. Connective tissue and its heritable disorders. Molecular, genetic and medical aspects. New York: Wiley-Liss. pp 533-548.
27. Schaffer MR, Efron PA, Thornton FJ, Klingel K, Gross SS, Barbul A. 1997. Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol 158:2375-2381.
28. Schroeter H, Boyd C, Spencer JP, Williams RJ, Cadenas E, Rice-Evans C. 2002. MAPK signaling in neurodegeneration: Influences of flavonoids and of nitric oxide. Neurobiol Aging 23:861-880.
29. Shi HP, Most D, Efron DT, Tantry U, Fischel MH, Barbul A. 2001. The role of iNOS in wound healing. Surgery 130:225-229.
30. Songyang Z, Lu KP, Kwon YT, Tsai LH, Filhol O, Cochet C, Brickey DA, Soderling TR, Bartleson C, Graves DJ, DeMaggio AJ, Hoekstra MF, Blenis J, Hunter T, Cantley LC. 1996. A structural basis for substrate specificities of protein Ser/Thr kinases: Primary sequence preference of casein kinases I and II, NIMA, phosphorylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1. Mol Cell Biol 16:6486-6493.
31. Surazynski A, Palka J, Wolczykski S. 2001. Phosphorylation of prolidase increases the enzyme activity. Mol Cell Biochem 220:95-101.
32. Taylor BS, Geller DA. 2000. Molecular regulation of the human inducible nitric oxide synthase (iNOS) gene. Shock 13:413-424.
33. Tsuruda T, Costello-Boerrigter LC, Burnett JC, Jr. 2004. Matrix metalloproteinases: Pathways of induction by bioactive molecules. Heart Fail Rev 9:53-61.
34. Witte MB, Barbul A. 2002. Role of nitric oxide in wound repair. Am J Surg 183:406-412.
35. Yaffe MB, Smerdon SJ. 2004. The use of in vitro peptide-library screens in the analysis of phosphoserine/threonine-binding domain structure and function. Annu Rev Biophys Biomol Struct 33:225-244.